Clinical Trial Update: Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension. [Phase 3]

View source ↗

Summary

Phase 3b study evaluating remibrutinib vs placebo with omalizumab as active control in adult chronic spontaneous urticaria, with an optional 52-week open-label …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spontaneous Urticaria

Drugs mentioned

• Omalizumab (Omalizumab)
• Remibrutinib (remibrutinib)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Spontaneous Urticaria | Phase 3 | Status: ACTIVE_NOT_RECRUITING